SK Biopharmaceuticals Forecast, price target & analysts
SK Biopharmaceuticals Target price 2024 - Analyst rating & recommendation
SK Biopharmaceuticals Classifications & Recommendation:
SK Biopharmaceuticals Target price
| Target price | KRW105,643.00 |
| Course | KRW77,500.00 |
| Price potential |
36.31%
register free of charge
|
| Number of estimates | 14 |
|
14 Analysts have issued a price target SK Biopharmaceuticals 2025 .
The average SK Biopharmaceuticals target price is KRW105,643.00.
This is
36.31%
register free of charge
KRW130,000.00
67.74%
register free of charge
KRW54,000.00
30.32%
register free of charge
|
|
| A rating was issued by 15 analysts: 11 Analysts recommend SK Biopharmaceuticals to buy, 2 to hold and 2 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst estimates: Analysts believe that the SK Biopharmaceuticals share has an average upside potential 2025 of
36.31%
register free of charge
|
Sales and margin forecast 2024, 2025 & 2026
| Dec '23 |
2024 Forecast |
|
|---|---|---|
| Turnover Billion KRW | 354.89 | 490.75 |
| 44.16% | 38.28% | |
| EBITDA margin | -6.42% | 14.15% |
| 86.62% | 320.48% | |
| Net margin | -9.27% | 10.18% |
| 83.64% | 209.87% |
15 Analysts have issued a sales forecast SK Biopharmaceuticals 2024 . The average SK Biopharmaceuticals sales estimate is
This results in the following potential growth figures:
15 Analysts have issued an SK Biopharmaceuticals EBITDA forecast 2024. The average SK Biopharmaceuticals EBITDA estimate is
This results in the following potential growth figures and future EBITDA margins:
2 SK Biopharmaceuticals Analysts have issued a net profit forecast 2024. The average SK Biopharmaceuticals net profit estimate is
This results in the following potential growth figures and future net margins:
Earnings per share, P/E ratio and EV/sales forecast 2024, 2025 & 2026
| Dec '23 |
2024 Forecast |
|
|---|---|---|
| Earnings per share KRW | -419.89 | 638.00 |
| 76.42% | 251.94% | |
| P/E ratio | 121.47 | |
| EV/Sales | 11.98 |
2 Analysts have issued a SK Biopharmaceuticals forecast for earnings per share. The average SK Biopharmaceuticals <a href=/blog/eps>EPS is
This results in the following potential growth figures and future valuations:
Based on analysts' sales estimates for 2024, the SK Biopharmaceuticals share is valued at an <a href=/blog/ev-sales-einfach-erklaert>EV/Sales of
This results in the following potential growth figures and future valuations:
SK Biopharmaceuticals...
Discover more stocks with a high price target
Register for free
StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.
